Glibenclamide Posttreatment Does Not Inhibit Levcromakalim Induced Headache in Healthy Participants: A Randomized Clinical Trial

Intravenous infusion of ATP-sensitive potassium channel (K(ATP)) opener levcromakalim causes headache in humans and implicates K(ATP) channels in headache pathophysiology. Whether K(ATP) channel blocker glibenclamide inhibits levcromakalim-induced headache has not yet been elucidated. We aimed to in...

Descripción completa

Detalles Bibliográficos
Autores principales: Kokoti, Lili, Al-Karagholi, Mohammad Al-Mahdi, Waldorff Nielsen, Cherie Amalie, Ashina, Messoud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10121935/
https://www.ncbi.nlm.nih.gov/pubmed/36763326
http://dx.doi.org/10.1007/s13311-023-01350-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10121935/
https://www.ncbi.nlm.nih.gov/pubmed/36763326
http://dx.doi.org/10.1007/s13311-023-01350-y

Ejemplares similares